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patients. This memorandum wants to point out the missing dif-
ference in TTSP and encourage clinicians to discuss both courses
with their patients.
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To the Editor:
The main focus of our paper concerns the potential role of cyto-
toxic chemotherapy, which needs to be considered in the context
of other standards of care [1]. As stated, the current standard of
care for advanced HCC is sorafenib. An exhaustive review of the
SHARP [2] and AP [3] trial data was not within the scope of our
review since these have been covered extensively in previous
publications. We do, however, highlight both the survival beneﬁt
and the toxicity associated with sorafenib. Survival remains the
primary end point for most phase III trials and is both robust
and, as Dr. Strebel points out, relevant to patients. Similarly, the
assessment of toxicity using National Cancer Institute’s Common
Terminology Criteria is well validated. However, the assessment
of time to symptomatic progression (TTSP) was done using
change in performance status and the Functional Assessment of
Cancer Therapy (FACT) Hepatobiliary Symptom Index 8 (FHSI-
8). The FHSI-8 is a tool developed to assess symptoms in hepatob-
iliary cancer patients in general and is not speciﬁc for HCC
patients. It has been validated in only one small study of 51
patients of which only 10 had HCC [4]. Furthermore, the ability
of the tool to detect clinically meaningful changes over time
has not been determined. Although TTSP was a primary end
point, the trial was not speciﬁcally powered to detect a difference
in TTSP. Hence, the lack of difference between the control and
treatment group may be due to the use of an insensitive tool, lack
of statistical power or real.
In discussing the option of sorafenib with patients, it is clearly
important to fully inform them of the known beneﬁts and the
main toxicities. However, unless the patient has to pay person-
ally, we do not agree that patients with advanced cancer should
be advised of the cost of the treatment. Such information implies
that the patient must judge whether their life is worth the cost.
We believe the question of cost-effectiveness is one for the
healthcare providers.Conﬂict of interest
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